Skip to main content

Table 3 mRNA expression levels in normal and breast cancer subtypes

From: Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

Gene Subtype or normal a Log 2 (normalized counts) b Comparison with basal c
CDC2L1 Normal 9.39 ± 0.38 0.90
  Basal 9.51 ± 0.5 N/A
  Her2 9.45 ± 0.61 1
  Luminal A 9.46 ± 0.4 1
  Luminal B 9.33 ± 0.57 0.049
CDC2L2 Normal 8.35 ± 0.76 d
  Basal 8.37 ± 0.79 N/A
  Her2 8.49 ± 0.84
  Luminal A 8.44 ± 0.69
  Luminal B 8.24 ± 0.95
CCNL1 Normal 10.82 ± 0.58 1.37 × 10 −14
  Basal 10.15 ± 0.56 N/A
  Her2 9.7 ± 0.49 9.68 × 10 −7
  Luminal A 9.87 ± 0.55 2.17 × 10 −5
  Luminal B 9.85 ± 0.49 2.10 × 10 −5
CCNL2 Normal 10.79 ± 0.48 1.90 × 10 −11
  Basal 10.2 ± 0.71 N/A
  Her2 10 ± 0.73 1
  Luminal A 10.38 ± 0.7 0.21
  Luminal B 10.28 ± 0.7 1
CSNK2A1 Normal 10.22 ± 0.2 5.50 × 10 −15
  Basal 10.74 ± 0.64 N/A
  Her2 10.75 ± 0.51 1
  Luminal A 10.53 ± 0.39 9.20 × 10 −3
  Luminal B 10.68 ± 0.61 1
CSNK2A2 Normal 9.36 ± 0.3 1
  Basal 9.3 ± 0.39 N/A
  Her2 8.92 ± 0.56 3.89 × 10 −5
  Luminal A 8.56 ± 0.45 2.06 × 10 −49
  Luminal B 8.64 ± 0.47 2.99 × 10 −33
CSNK2B Normal 10.96 ± 0.28 3.03 × 10 −38
  Basal 11.78 ± 0.5 N/A
  Her2 11.52 ± 0.39 1.91 × 10 −3
  Luminal A 11.25 ± 0.42 4.04 × 10 −22
  Luminal B 11.43 ± 0.54 8.24 × 10 −8
  1. Her2, human epidermal growth factor receptor 2; N/A, not applicable. aNormal, n = 95; basal, n = 141; Her2, n = 67; luminal A, n = 421; luminal B, n = 192. bRNAseq data from The Cancer Genome Atlas expressed as mean ± standard deviation. cComparison with basal subtype, P value with Bonferroni correction; significant P values in bold type. dAnalysis of variance comparing CDC2L2 expression across subtypes revealed no significant differences, so no pairwise t tests were performed.